Gaudium IVF Q1 PAT falls 42% YoY to Rs1.78 Cr on expansion spend; revenue up 9%

Gaudium IVF's Q1 FY27 consolidated (primary) revenue rose 9.1% YoY to Rs19.38 Cr (Rs17.76 Cr a year ago) but consolidated PAT fell 42.3% YoY to Rs1.78 Cr (Rs3.08 Cr) - profit trailing revenue by a wide margin is the defining feature of the quarter. Standalone tells a shallower version of the same story: PAT down 29.2% YoY to Rs1.66 Cr on revenue up 11.4% to Rs13.68 Cr. The roughly 13-point gap between the standalone and consolidated PAT declines is a real divergence (>3%) and readers comparing the two bases should note consolidated is the weaker number. Sequentially, both revenue (-36.2% QoQ from Rs30.35 Cr) and PAT (-78.7% QoQ from Rs8.36 Cr) look sharply weaker, but the Q4 FY26 comparator is itself a derived 'balancing figure' between the audited full year and the reviewed nine-month numbers (per the auditor's note), not an independently reported quarter - so the QoQ swing is partly a base-quality artifact, and the YoY read is the one to anchor on. The compression sits squarely on the expense side, not revenue. Consolidated OPM nearly halved to 12.5% from 29.0% a year ago, and NPM fell to 8.7% from 17.3%, driven by sales and marketing spend that jumped 148% YoY to Rs4.04 Cr (+71% sequentially) and employee benefit expense up 25% YoY to Rs2.28 Cr - both tied to staffing and go-to-market costs for the FY27 hub rollout. Partially offsetting this, finance costs fell 24% YoY to Rs0.38 Cr after the company repaid its entire Rs18.07 Cr of outstanding borrowings during the quarter using IPO proceeds, removing what had been a meaningful cost line. The company carries no analyst consensus or brokerage coverage that a search could find - it listed only in February 2026, and no Q1 FY27 estimates or initiation reports surfaced, so vsStreet is unknown. There is likewise no formal prior guidance on record and none turned up in search; management gives no formal guidance and the only forward framing accompanies this print itself. Operationally, the quarter included commencement of a new Delhi centre (July 15) and the launch of an AI-powered diagnostics lab as the company began its planned 19-centre expansion (July 16); of the Rs50 Cr IPO allocation earmarked for new-centre capex, only Rs1.03 Cr had been deployed as of June 30, 2026, so the bulk of that investment - and its revenue contribution - is still ahead. Management's own framing, from the press release, calls the quarter 'a period of measured progress' with revenue growth 'reflecting the resilience of our mature hubs,' while explicitly describing profitability as 'consciously moderated' to fund 'clinical talent, systems and readiness' for the ten hubs planned this year - directly consistent with the margin and cost-line detail above. The read-through for coming quarters is whether the expansion spend converts into revenue fast enough to rebuild margins before FY27 capex ramps further - 12.5% OPM is the level to track against the 29-40% range seen over the past four quarters.